'On consolidated basis

Quarter ended September 2024 compared with Quarter ended September 2023.

Net sales (including other operating income) of Torrent Pharmaceuticals has increased 8.61% to Rs 2889 crore.  Operating profit margin has jumped from 31.02% to 32.50%, leading to 13.82% rise in operating profit to Rs 939.00 crore.  Raw material cost as a % of total sales (net of stock adjustments) decreased from 15.89% to 11.50%.   Purchase of finished goods cost rose from 10.72% to 13.04%.   Employee cost increased from 18.46% to 18.53%.   Other expenses rose from 24.66% to 24.88%.   

PBIDT rose 8.46% to Rs 923 crore.  Provision for interest fell 29.67% to Rs 64 crore.  Loan funds declined from Rs 4,487.00 crore as of 30 September 2023 to Rs 3,128.00 crore as of 30 September 2024.  Sundry debtors were higher at Rs 1,783.00 crore as of 30 September 2024 compared to Rs 1...

• 

  (13-Jan-2025)

  Avenue Supermarts

  Revenue up 17.7% YoY, Net profit up 4.8% YoY in Q3FY2025

• 

  (12-Jan-2025)

  Just Dial

  Sales up 8%, net up 43%

• 

  (10-Jan-2025)

  PCBL

  Lower profits

• 

  (10-Jan-2025)

  Tata Consultancy Services

  Revenue up 5.6% YoY to Rs 63973 crore in Q3FY2025